Radioligand Therapy Market: Current Analysis and Forecast (2021-2027)


Emphasis on Products (Approved Products and Potential Pipeline); Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others); Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression, and Grading, Cytochrome P450 17A1 Inhibitor); and Region/Country

Detailed Analysis of COVID-19 Impact on the Radioligand Therapy Market







Report ID:



  Get a Sample
SKU: UMHE21850 Categories: ,
Report Description
Table of content
Research Methodology

Report Description

Radioligand Therapy Market
Radioligand Therapy Market


The global radioligand therapy market is experiencing significant growth due to the increasing geriatric population, skin issues caused by sun rays, and awareness regarding personal hygiene among consumers. For instance, in January 2020, L’Oréal S.A. unveiled an artificial intelligence (AI)-enabled at-home skincare device, named Perso. It is equipped with a patented motorized system that allows it to provide personalized skincare formulas for customers (in the form of moisturizers, serums, and under-eye creams) based on real-time data and trend analysis. The Perso device is operable via Bluetooth and is NFC (Near-field Communication) compliant, which means that it works best in tandem with a smartphone. Thus, with the growing focus on technology and smartphones used by consumers which gives detailed information across the world. Therefore, the market for radioligand therapy is expected to witness a significant CAGR of 4% during the forecast period.

The global radioligand therapy market is expected to register a CAGR of around 4% from 2021 to 2027. This is mainly due to the rapid advancement in technology and celebrity endorsements are responsible for the market growth of radioligand therapy. Furthermore, the increasing income of the people significantly contributes to the market for radioligand therapies. As per the World Health Organization (WHO), cancer is the second leading cause of death worldwide and is responsible for around 9.6 million deaths in 2018. Moreover, the increasing elderly population of the country is also responsible for boosting the market because older adults are more likely to have chronic health conditions, such as diabetes or heart disease. However, the high cost of development of the radioligand therapies and the side effects associated with the treatment are expected to hinder the market growth over the forecast period. Furthermore, according to the American Cancer Society, in 2019, around 174,650 new cases of prostate cancer were diagnosed in the U.S. The demand for radioligand products also increased due to the rising prevalence of medical conditions like hormonal imbalance in the population. Therefore, the market for radioligand therapy is expected to witness significant growth during the forecast period.

Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc., and Bayer AG. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.


Insights Presented in the Report

“Amongst Products, approved product segment accounted for the majority share in the market in 2020”

Amongst product, the approved products category accounted for a significant share of the market. This is mainly due to the presence of a wide range of products and the advent of novel and improved methods that are FDA-approved and more effective procedures such as lutetium 177, prostate-specific membrane antigen (PSMA), and other approved products for the treatment of cancer and development of the radioligand therapies. The strategic acquisition by leading players operating in radioligand therapy is helping manufacturers in expanding the cancer product pipeline. Thus, approval and commercialization of pipeline products soon are expected to propel the market during the forecast period.

“Amongst biomarker, prostate-specific membrane antigen is expected to witness highest CAGR during the forecast period”

Based on the biomarker, the market is categorized into prostate-specific membrane antigen, ki 67 expressions, and grading, cytochrome p450 17a1 inhibitor. Among these, prostate-specific membrane antigen is expected to witness the highest CAGR during the forecast period. For instance, as per PubMed, radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) after radioligand therapy. The continuous development of the new products and procedures is likely to strengthen the market of the segment during the forecast period.

“North America to witness significant growth during the forecast period”

North America is expected to show significant growth in the global market. The major contributors to the growth of this market are US and Canada. The increase in technology development in emerging economies, as well as the expansion of the beauty industry, has contributed to the growth of the North American market. North America has a higher adoption rate of technologically advanced and innovative solutions and devices. The enhanced consumer awareness regarding the availability of various radioligand therapies rise in the patient base suffering from cancer has propelled the growth of the market in the region. Hence these require research & development of radioligand therapy in the region which drives the demand for radioligand therapy. Furthermore, increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth. The endorsement manufacturers are focused to enter into partnerships with laboratories also significantly contributed to the considerable growth of the state in the U.S.


Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.

Customization Options:

The global radioligand therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

1.1.Market Definitions
1.4.Currency used in Report
2.1.Research Process of the Radioligand Therapy Market
2.2.Research Methodology of the Radioligand Therapy Market
2.3.Forecasting Method
2.4.Respondent Profile
2.5.Main Objective of the Radioligand Therapy Market Study




7.1.Approved Products
7.2.Potential Pipeline
8.1.Prostate Cancer
8.2.Neuroendocrine Tumor (NETs)
9.1.Prostate-Specific Membrane Antigen
9.2.Ki 67 Expression and Grading
9.3.Cytochrome P450 17A1 Inhibitor
10.1.North America
 10.1.3.Rest of North America 
 10.2.6.Rest of Europe
 10.3.5.Rest of Asia-Pacific
10.4.Rest of World
11.1.Market Drivers
11.2.Market Challenges
11.3.Impact Analysis
15.1.Demand Side Analysis
15.2.Supply Side Analysis
17.1.Competitive Landscape
 17.1.1.Porter’s Five Forces Analysis 
18.1.Johnson & Johnson Services Inc.
18.2.Pfizer Inc. 
18.3.Amneal Pharmaceuticals LLC
18.4.Novartis International AG
18.5.POINT Biopharma Global Inc
18.6.Fusion Pharma
18.7.Clovis Oncology
18.8.Telix Pharmaceuticals
18.9.Lantheus Holdings, Inc.
18.10.Bayer AG. 

Research Methodology

Analyzing the historical market, estimation of the current market, and forecasting the future market of the global radioligand therapy market were the three major steps undertaken to create and analyze the adoption of radioligand therapy in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global radioligand therapy market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Seek More Details About Research Methodology

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detail secondary study was conducted to obtain the historical market size of the radioligand therapy market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the radioligand therapy market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as product, indication, biomarker, and region. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the radioligand therapy market. Further, we conducted factor analysis using dependent and independent variables such as product, indication, biomarker, and region of radioligand therapy. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the Radioligand therapy market sector across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global radioligand therapy market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.


Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast about 2027 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of radioligand therapy market across the major markets domestically
  • All percentage shares, splits, and breakdowns of market segments and sub-segments
  • Key players in the global radioligand therapy market in terms of solutions offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Radioligand Therapy Market
Radioligand Therapy Market


Market Engineering

Data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global radioligand therapy market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of product, indication, biomarker, and region in the global radioligand therapy market.

The main objective of the Global Radioligand therapy Market Study

The current & future market trends of the global radioligand therapy market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the radioligand therapy market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of product, indication, biomarker, and region.
  • Define and analysis of the regulatory framework for the radioligand therapy market industry.
  • Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
  • Analyze the current and forecast market size of the radioligand therapy market for the major region.
  • Major countries of regions studied in the report include North America, Europe, Asia Pacific, and Rest of the world.
  • Company profiles of the Radioligand therapy market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Deep dive regional level analysis of the industry

You can also purchase parts of this report. Do you want to check out a section wise
price list?